INIS
plasma
80%
patients
59%
levels
57%
inflammation
44%
glucose
42%
concentration
32%
lysine
30%
diseases
29%
mice
29%
intake
28%
screening
28%
diet
27%
humans
24%
risks
24%
glyoxal
23%
proteins
23%
receptors
23%
insulin
22%
adults
20%
tools
19%
control
19%
hydrogen 1
18%
sensitivity
18%
comparative evaluations
17%
therapy
17%
accumulation
16%
interventions
16%
fasting
16%
tissues
15%
tolerance
15%
data
15%
skin
14%
collagen
14%
reviews
14%
hypoxia
14%
kidneys
14%
biological markers
12%
urine
12%
cardiovascular diseases
12%
males
12%
glycolysis
11%
mass spectrometry
11%
atherosclerosis
10%
reliability
9%
liver
9%
precursor
9%
enzymes
9%
metabolites
9%
cancer
9%
fructose
9%
placenta
9%
liquid column chromatography
9%
metabolism
8%
food
8%
values
8%
doses
8%
blood pressure
8%
men
8%
quercetin
7%
weight
7%
populations
7%
females
7%
hospitals
7%
angiotensin
7%
lactates
7%
monocytes
7%
losses
6%
mortality
6%
diabetes mellitus
6%
assessments
6%
people
6%
damage
6%
genes
6%
adhesion
6%
ornithine
5%
metastases
5%
performance
5%
boron 6
5%
coupling
5%
clinical trials
5%
detection
5%
albumins
5%
Keyphrases
Methylglyoxal
100%
Advanced Glycation End Products
96%
Dicarbonyls
49%
Maastricht
36%
Glyoxal
21%
Obese Men
21%
3-deoxyglucosone
20%
Frailty Screening
18%
Diabetes
17%
Protein Binding
17%
Type 1 Diabetes Mellitus (T1DM)
16%
Inflammation
15%
MG-H1
15%
Glyoxalase
14%
Hospitalized Patients
14%
Older Hospitalized Patients
14%
Pyridoxamine
14%
Skin Autofluorescence
14%
Insulin Sensitivity
12%
Oral Glucose Tolerance Test
11%
Low-grade Inflammation
11%
Non-associated
11%
Delirium
11%
High Performance Liquid Chromatography-tandem Mass Spectrometry (HPLC-MS/MS)
10%
Type 2 Diabetes Mellitus (T2DM)
10%
Frail Elderly
10%
Vascular Function
10%
Type I Diabetes
10%
Randomized Controlled Trial
10%
Plasma Glucose
9%
End-stage Renal Disease
9%
Pre-diabetes (pre-DM)
9%
Gut Microbiota Composition
9%
Glycation
9%
Renal Replacement Therapy
9%
Hospitalized Older Adults
9%
Endothelial Dysfunction
9%
Fructose
9%
Preeclampsia
9%
Lysine
9%
Dietary Dicarbonyls
8%
SRAGE
8%
Hypoxia
8%
Screening Tool
8%
Dicarbonyl Stress
7%
Frailty
7%
Plasma Concentration
7%
Dicarbonyl Compounds
7%
Vascular Complications
7%
Glycolysis
7%
Plasma Parameters
6%
Dutch
6%
Dietary Advanced Glycation End Products
6%
Patients with Diabetes
6%
Insulin
6%
Insulin Resistance
6%
Habitual Intake
6%
Glucose Excursion
6%
Reliability Validity
6%
Quercetin
6%
Habitual Diet
6%
MS Method
5%
Lactate
5%
Sensitivity Function
5%
Carboxymethyllysine
5%
Glucose Metabolism
5%
Oral Glucose
5%
Non-diabetic
5%
Placebo-controlled
5%
Randomized Double-blind
5%
Scavenger
5%
Without Diabetes
5%
Inpatient Hospitals
5%
Non-frail
5%
Clinical Practice
5%
B6 Vitamers
5%
Hemoglobin A1c (HbA1c)
5%
Frequently Consumed Foods
5%
Cross-sectional Observational Study
5%
Medicine and Dentistry
Methylglyoxal
54%
Advanced Glycation End-Product
49%
Diabetes
16%
Pyridoxamine
14%
Insulin Dependent Diabetes Mellitus
11%
Atherosclerosis
9%
Insulin Sensitivity
9%
Glycation
9%
Impaired Glucose Tolerance
9%
Randomized Controlled Trial
9%
Pre-Eclampsia
9%
Biological Marker
9%
Autofluorescence
9%
Glyoxalase
8%
Hypoxia
7%
6 N Carboxymethyllysine
7%
Advanced Glycation End Product Receptor
6%
Table Salt
6%
Metabolite
5%
Oral Glucose Tolerance Test
5%
Glyoxal
5%
Diabetes Mellitus
5%
Hemoglobin A1c
5%